[PDF] Top 20 <p>Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials</p>
Has 10000 "<p>Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials</p>" found on our website. Below are the top 20 most common "<p>Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials</p>".
<p>Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials</p>
... from nine randomized controlled trials (RCTs) were included for ...in advanced NSCLC significantly improved the possibility of archiving CR (RR ...1.44–5.81, P=0.003) compared to ... See full document
7
<p>A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer</p>
... of immune checkpoint inhibitors has led to a step forward in the treatment of advanced ...NSCLCs. Immune checkpoints such as PD-1/L1 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) were ... See full document
19
<p>Cinobufotalin as an effective adjuvant therapy for advanced gastric cancer: a meta-analysis of randomized controlled trials</p>
... University Cancer Hospital showed that cinobufotalin is well tolerated by hepa- tocellular carcinoma, non-small-cell lung cancer and pan- creatic cancer patients (only ... See full document
22
Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
... “non-small cell lung OR non- small cell lung carcinoma” and “randomized controlled trial OR controlled clinical trials, ...of ... See full document
11
<p>Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis</p>
... and meta-analysis of all randomized controlled trials that compare the ef fi cacy and safety of programmed death 1 (PD-1) inhibitors versus chemotherapy alone in previously ... See full document
12
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
... in advanced NSCLC, several trials have been designed to evaluate the feasibility and safety of combination strategies in neo- adjuvant ...were complete pathologic response ...pilot ... See full document
19
<p>Pseudo-Progression and the Neutrophil-to-Lymphocyte Ratio in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Case–Control Study</p>
... T cell lympho- cyte in fi ltration rather than an increase in viable tumour ...treatment response before lesions are visibly smaller on ...KRAS-mutated lung adenocarcinoma with ...is associated ... See full document
10
<p>Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis</p>
... ten trials evaluated CTLA-4 inhibitor (ipilimumab, n = 10), and four trials evaluated PD-1 inhibitor (nivolumab, n = 3; pembrolizumab, n = ...Two trials included three cohorts, so a pairwise ... See full document
10
<p>Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives</p>
... higher pneumonitis from previous chemoradiotherapy. The primary end points of the study were PFS and overall survival (OS). PFS, as assessed by a blinded independent central review, was signi fi cantly improved with ... See full document
10
Immune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment
... Abstract: Lung cancer is the major cause for cancer-related death in the ...metastatic non-small-cell lung cancer, its prognosis remains ...the immune system ... See full document
16
Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: a meta-analysis of Phase III randomized controlled trials
... III randomized controlled trials with a paral- lel design comparing docetaxel and pemetrexed or docetaxel and vinca alkaloid in advanced NSCLC patients; 2) they had to be randomized ... See full document
9
Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials
... of Controlled Trials (CEN- TRAL), PubMed (up to August 2015), and Web of Science (up to August 2015) databases were searched for articles using “bevacizumab”, “avastin”, “non-small-cell ... See full document
8
<p>Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review</p>
... or non-squamous NSCLC and metastatic or advanced ...of immune checkpoint inhibi- ...clinical trials: KEYNOTE 024, 13 KEYNOTE 042, 10 KEYNOTE 189, 14 KEYNOTE 407, 15 KEYNOTE 010 5 , ... See full document
16
Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report
... Third-line therapy with nivolumab was started on De- cember 11, 2015, given that no other viable treatment op- tions were available. PD-L1 staining was negative at diagnosis and not tested again at relapse. Within 2 h of ... See full document
5
<p>Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer</p>
... A 76-year-old female presented with persistent cough and chest tightness with a performance status (PS) of 1. Computed tomography (CT) scan showed a left inferior pul- monary nodule, multiple enlarged mediastinal lymph ... See full document
6
Prospects for combining immune checkpoint blockade with PARP inhibition
... ovarian cancer: PBM (driven by p53 depletion, BRCA1 depletion, and c- Myc overexpression) and PPM (driven by p53 depletion, PTEN depletion, and c-Myc overexpression) ...tumor immune microenvir- onment ... See full document
12
<p>Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges</p>
... T cell receptor ...the immune response mediated by activated T and NK ...or cell surface galectin 9 to negatively regulate T and NK cell ...NK cell attack. In contrast, in ... See full document
16
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
... of response to checkpoint in- hibitors are circulating tumor cells (CTC) and tumor- derived extracellular vesicles (tdEV) ...of cancer, including NSCLC ...be associated with worse survival ... See full document
9
Prognostic value of angiopoietin 2 in non small cell lung cancer patients: a meta analysis
... Background: Non-small cell lung cancer (NSCLC) is the most frequent cause of cancer deaths ...a meta-analysis to assess the relationship between Ang-2 and ... See full document
9
Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets
... PD-L1 inhibitors showed promising signs of efficacy, resulting in the initiation of several phase III trials and the recent approval of this combination for use in the USA by Food and Drug ... See full document
11
Related subjects